Abstract

As a common vector transfection tool, lentivirus has become the first choice for gene therapy of ophthalmic diseases because of its advantages of high efficiency, large transgene, and stable integration in host cells, such as ocular neovascular diseases applied to animal models, and retinal hereditary diseases, glaucoma, etc., have made some progress in research but have not been used clinically. The application of lentivirus focused on the ocular diseases such as Stargardt disease, diabetic retinopathy and corneal transplantation to lay the foundation for the study of the treatment of ophthalmic diseases through the regulation of gene expression.(Int Rev Ophthalmol, 2018, 42: 227-231) Key words: lentivirus; gene therapy; ophthalmology

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.